alzheimer's disease

Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study

Authors: Colin Sauder, Luke A Allen, Elizabeth Baker, Andrew C Miller, Steven M Paul, Stephen K Brannan

Journal: Translational Psychiatry

Year Published: 2022

The muscarinic receptor agonist xanomeline improved cognition in phase 2 trials in Alzheimer’s disease and schizophrenia. We present data on the effect of KarXT (xanomeline-trospium) on cognition in schizophrenia from the 5-week, randomised, double-blind, placebo-controlled EMERGENT-1 […]

Genetic polymorphism in BIN1 rather than APOE is associated with poor recognition memory among men without dementia

Authors: Kanika Mehta, Mohammadreza Mohebbi, Julie A Pasco, Lana J Williams, Ken Walder, Boon Lung Ng, Veer Bala Gupta

Journal: Scientific Reports

Year Published: 2022

Although several genetic polymorphisms have been linked with the risk of Alzheimer’s disease, less is known about their impact on cognitive performance among cognitively healthy individuals. Our aim was to investigate the association of the genetic […]

A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M 1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer’s disease

Authors: Pradeep J Nathan, S Babli Millais, Alex Godwood, Odile Dewit, David M Cross, Janet Liptrot, Bharat Ruparelia, Stephen Paul Jones, Geor Bakker, Paul T Maruff, Gregory A Light, Alastair J H Brown, Malcolm Peter Weir, Miles Congreve, Tim Tasker

Journal: Alzheimer's & Dementia

Year Published: 2022

Introduction: This study examined the safety and pharmacodynamic effects of selective muscarinic M1 receptor orthosteric agonist HTL0018318 in 60 patients with mild-to-moderate Alzheimer’s disease (AD) on background donepezil 10 mg/day. Methods: A randomized, double-blind, placebo-controlled 4-week […]

A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M 1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer’s disease

Authors: Pradeep J Nathan, S Babli Millais, Alex Godwood, Odile Dewit, David M Cross, Janet Liptrot, Bharat Ruparelia, Stephen Paul Jones, Geor Bakker, Paul T Maruff, Gregory A Light, Alastair J H Brown, Malcolm Peter Weir, Miles Congreve, Tim Tasker

Journal: Alzheimer's & Dementia : Translational Research & Clinical Interventions

Year Published: 2022

Introduction: This study examined the safety and pharmacodynamic effects of selective muscarinic M1 receptor orthosteric agonist HTL0018318 in 60 patients with mild-to-moderate Alzheimer’s disease (AD) on background donepezil 10 mg/day. Methods: A randomized, double-blind, placebo-controlled 4-week […]

Elucidating the association between depression, anxiety, and cognition in middle-aged adults: Application of dimensional and categorical approaches

Authors: Stephanie Perin, Janice Lai, Matthew Pase, Lisa Bransby, Rachel Buckley, Nawaf Yassi, Robert H Pietrzak, Paul Maruff, Yen Ying Lim

Journal: Journal of Affective Disorders

Year Published: 2022

Background: In older adults, depressive and anxiety symptoms are associated with dementia risk, and represent a manifestation of the dementia prodrome. Understanding how these symptoms are related to cognition in midlife may inform risk models of […]

1 2 3 4

Back to Publications